SLC5A2 and hydrops fetalis: Meta-analyses of intensive glucose control studies, including Action to Control Cardiovascular Risk in Diabetes (ACCOD), Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE), UKPDS, and Veterans Affairs Diabetes Trial (VADT), that used antidiabetic drugs other than SGLT2 inhibitors for glycemic control, showed a significant 15% decrease in the risk of myocardial infarction but no prevention of HF in T2DM patients in the almost five-year observation period [47].